Synpromics, UCL to develop gene therapy for PD

Synpromics Ltd. (Edinburgh, U.K.) partnered with University College London to generate synthetic CNS gene promoters and develop a gene therapy for Parkinson's disease.

The partners will jointly develop promoters that specifically control the expression of therapeutic genes in different sub-populations of neurons. UCL will then use the gene switches to develop gene therapy vectors to treat young-onset PD. ...